Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-016-1278-6) contains supplementary material, which is available to authorized users.
Patient-reported data are playing an increasing role in health care. In oncology, data from quality of life (QoL) assessment tools may be particularly important for those with limited survival prospects, where treatments aim to prolong survival while maintaining or improving QoL. This paper examines the use and impact of using QoL measures on health care of cancer patients within a clinical setting, particularly those with brain cancer. It also examines facilitators and challenges, and provides implications for policy and practice.
We conducted a systematic literature review, 15 expert interviews and a consultation at an international summit.
The systematic review found no relevant intervention studies specifically in brain cancer patients, and after expanding our search to include other cancers, 15 relevant studies were identified. The evidence on the effectiveness of using QoL tools was inconsistent for patient management, but somewhat more consistent in favour of improving patient–physician communication. Interviews identified unharnessed potential and growing interest in QoL tool use and associated challenges to address.
Our findings suggest that the use of QoL tools in cancer patients may improve patient–physician communication and have the potential to improve care, but the tools are not currently widely used in clinical practice (in brain cancer nor some other cancer contexts) although they are in clinical trials. There is a need for further research and stakeholder engagement on how QoL tools can achieve most impact across cancer and patient contexts. There is also a need for policy, health professional, research and patient communities to strengthen information exchange and debate, support awareness raising and provide training on tool design, use and interpretation.
Dirven, L., Reijneveld, J. C., Aaronson, N. K., Bottomley, A., Uitdehaag, B. M., & Taphoorn, M. J. (2013). Health-related quality of life in patients with brain tumors: Limitations and additional outcome measures. Current Neurology and Neuroscience Reports, 13(7), 359. doi: 10.1007/s11910-013-0359-y. CrossRefPubMed
Mauer, M. E., Bottomley, A., & Taphoorn, M. J. (2008). Evaluating health-related quality of life and symptom burden in brain tumour patients: Instruments for use in experimental trials and clinical practice. Current Opinion in Neurology, 21(6), 745–753. doi: 10.1097/WCO.0b013e328315ef7d. CrossRefPubMed
Taphoorn, M. J., van den Bent, M. J., Mauer, M. E., et al. (2007). Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: Results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. Journal of Clinical Oncology, 25(36), 5723–5730. doi: 10.1200/jco.2007.12.7514. CrossRefPubMed
Armstrong, T. S., Wefel, J. S., Wang, M., et al. (2013). Net clinical benefit analysis of radiation therapy oncology group 0525: A phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 31(32), 4076–4084. doi: 10.1200/jco.2013.49.6067. CrossRefPubMedPubMedCentral
Soffietti, R., Kocher, M., Abacioglu, U. M., et al. (2013). A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. Journal of Clinical Oncology, 31(1), 65–72. doi: 10.1200/jco.2011.41.0639. CrossRefPubMed
Fairclough, D. L. (2002). Design and analysis of quality of life studies in clinical trials. Boca Raton: Chapman and Hall/CRC Press.
Mauer, M., Stupp, R., Taphoorn, M. J., et al. (2007). The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: Results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British Journal of Cancer, 97(3), 302–307. doi: 10.1038/sj.bjc.6603876. CrossRefPubMedPubMedCentral
Lipscomb, J., Gotay, C. C., & Snyder, C. F. (2007). Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA: A Cancer Journal for Clinicians, 57(5), 278–300. doi: 10.3322/ca.57.5.278.
Higgins, J. P. T., Altman, D. G., & Sterne, J. A. C. (2011). Assessing risk of bias in included studies. In J. P. T. Higgins & S. Green (Eds.), Cochrane handbook for systematic reviews of interventions: The cochrane collaboration, 2011.
Cochrane. Tool to assess risk of bias in cohort studies. Cochrane Methods Bias. http://bmg.cochrane.org/sites/bmg.cochrane.org/files/uploads/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf. Accessed December 8, 2015.
NIH. Quality Assessment tool for before-after (pre-post) studies with no control group. National Heart, Lung, and Blood Insitute 2014. http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/before-after. Accessed December 8, 2015.
Gubrium, J. F. (2012). The sage handbook of interview research: The complexity of the craft. New York: Sage. CrossRef
Klinkhammer-Schalke, M., Koller, M., Steinger, B., et al. (2012). Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: Randomised trial in 200 women with breast cancer. British Journal of Cancer, 106(5), 826–838. doi: 10.1038/bjc.2012.4. CrossRefPubMedPubMedCentral
Wolfe, J., Orellana, L., Cook, E. F., et al. (2014). Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: Results from the PediQUEST randomized controlled trial. Journal of Clinical Oncology, 32(11), 1119–1126. doi: 10.1200/jco.2013.51.5981. CrossRefPubMedPubMedCentral
McLachlan, S. A., Allenby, A., Matthews, J., et al. (2001). Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer. Journal of Clinical Oncology, 19(21), 4117–4125. PubMed
Rosenbloom, S. K., Victorson, D. E., Hahn, E. A., Peterman, A. H., & Cella, D. (2007). Assessment is not enough: A randomized controlled trial of the effects of HRQL assessment on quality of life and satisfaction in oncology clinical practice. Psycho-Oncology, 16(12), 1069–1079. doi: 10.1002/pon.1184. CrossRefPubMed
Velikova, G., Keding, A., Harley, C., et al. (2010). Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: Secondary outcomes of a randomised controlled trial. European journal of cancer (Oxford, England : 1990), 46(13), 2381–2388. doi: 10.1016/j.ejca.2010.04.030. CrossRef
Efficace, F., Bottomley, A., Osoba, D., et al. (2003). Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials—Does HRQOL evaluation in prostate cancer research inform clinical decision making? Journal of Clinical Oncology, 21(18), 3502–3511. doi: 10.1200/jco.2003.12.121. CrossRefPubMed
Efficace, F., & Bottomley, A. (2002). Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. European Journal of Cancer (Oxford, England: 1990), 38(14), 1824–1831. CrossRef
- The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: insights from a systematic review and stakeholder consultations
- Springer International Publishing